Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Zabilugene almadenorepvec - Synthetic Biologics

Next Previous
Drug Profile

Zabilugene almadenorepvec - Synthetic Biologics

Alternative Names: VCN-01

Latest Information Update: 27 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator VCN Biosciences
  • Developer AstraZeneca; Theriva Biologics; VCN Biosciences
  • Class Antineoplastics; Eye disorder therapies; Gene therapies; Immunotherapies; Oncolytic viruses
  • Mechanism of Action Cell death stimulants; Hyaluronidase stimulants; Immunologic cytotoxicity
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Adenocarcinoma; Retinoblastoma
  • New Molecular Entity No

Highest Development Phases

  • Phase II Adenocarcinoma
  • Phase I/II Pancreatic cancer; Retinoblastoma; Squamous cell cancer
  • No development reported Brain cancer; Ovarian cancer; Solid tumours

Most Recent Events

  • 14 May 2025 Theriva Biologics plans a phase III registrational trial for Adenocarcinoma (Pancreatic ductal adenocarcinoma) (Combination therapy)
  • 07 May 2025 Efficacy data from a phase II trial in Pancreatic cancer released by Theriva Biologics
  • 31 Mar 2025 Theriva Biologics plans an End-of-phase II meeting with the US FDA and EMA for the phase III trial for Adenocarcinoma (Metastatic disease) before the end of 2025

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top